Woodstock Corp Purchases 764 Shares of Eli Lilly and Company (NYSE:LLY)


Share on StockTwits

Woodstock Corp lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 16.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,282 shares of the company’s stock after purchasing an additional 764 shares during the period. Woodstock Corp’s holdings in Eli Lilly and were worth $987,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Perennial Advisors LLC purchased a new stake in Eli Lilly and during the fourth quarter worth about $31,000. Retirement Group LLC purchased a new stake in Eli Lilly and during the fourth quarter worth about $33,000. DB Wealth Management Group LLC purchased a new stake in Eli Lilly and during the fourth quarter worth about $34,000. Accel Wealth Management purchased a new stake in Eli Lilly and during the fourth quarter worth about $37,000. Finally, Archer Investment Corp increased its holdings in Eli Lilly and by 83.3% during the fourth quarter. Archer Investment Corp now owns 220 shares of the company’s stock worth $37,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 75.59% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 13th. The shares were sold at an average price of $185.97, for a total transaction of $39,053,700.00. Following the completion of the transaction, the insider now owns 110,807,418 shares of the company’s stock, valued at $20,606,855,525.46. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders have sold 555,284 shares of company stock valued at $106,132,302. 0.09% of the stock is owned by corporate insiders.

LLY has been the subject of a number of research analyst reports. Bank of America raised their price objective on shares of Eli Lilly and from $195.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, January 22nd. Truist Securities raised their price objective on shares of Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, March 22nd. Mizuho lifted their target price on shares of Eli Lilly and from $222.00 to $228.00 and gave the stock a “buy” rating in a research note on Monday, February 1st. Barclays lifted their target price on shares of Eli Lilly and from $190.00 to $232.00 and gave the stock an “overweight” rating in a research note on Monday, February 1st. Finally, Truist lifted their target price on shares of Eli Lilly and from $200.00 to $215.00 in a research note on Monday, February 1st. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $193.88.

NYSE:LLY traded up $0.74 during mid-day trading on Thursday, hitting $183.06. 17,789 shares of the stock traded hands, compared to its average volume of 4,374,581. The business’s 50-day moving average price is $195.68 and its 200 day moving average price is $171.39. The company has a market cap of $175.55 billion, a PE ratio of 29.79, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. Eli Lilly and Company has a 12-month low of $129.21 and a 12-month high of $218.00. The company has a quick ratio of 1.06, a current ratio of 1.36 and a debt-to-equity ratio of 3.27.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Thursday, January 28th. The company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.35 by $0.40. The company had revenue of $7.44 billion during the quarter, compared to analysts’ expectations of $7.27 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. Eli Lilly and’s revenue for the quarter was up 21.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.73 earnings per share. Analysts anticipate that Eli Lilly and Company will post 7.56 earnings per share for the current fiscal year.

Eli Lilly and Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More: What is the Consumer Price Index (CPI)?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.